VTRS

+ Watchlist + Portfolio

Viatris Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $16.00
52-Week Range: $9.43 – $18.39
Market Cap: $18.67B
P/E (TTM): —
EPS (TTM): -0.37
Dividend Yield: 2.98%

Advanced Metrics

Price/Book: 1.29
PEG Ratio: 1.05
Return on Equity: -2.75%
Return on Assets: 2.67%
Gross Margin: 40.31%
Operating Margin: 12.55%
Profit Margin: -2.79%
Current Ratio: 1.58
Debt/Equity: 0.96
Total Debt: $13.62B
Free Cash Flow: $2.68B
Revenue Growth: 4.90%
Earnings Growth: —
Enterprise Value: $30.63B

VTRS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$16.26B	$15.43B	$14.74B	$14.30B
Cost of Revenue	$9.77B	$8.99B	$9.12B	$9.29B
Gross Profit	$6.50B	$6.44B	$5.62B	$5.01B
Research & Development	$662.20M	$805.20M	$808.70M	$965.90M
Selling, General & Admin	$4.18B	$4.07B	$4.10B	$3.79B
Operating Expenses	$4.84B	$4.88B	$4.91B	$4.76B
Operating Income	$1.66B	$1.56B	$710.30M	$253.50M
EBITDA	$6.43B	$3.52B	$2.82B	-$395.40M
Pretax Income	$2.81B	$202.90M	-$623.20M	-$3.67B
Income Tax	$734.60M	$148.20M	$11.00M	-$150.10M
Net Income	$2.08B	$54.70M	-$634.20M	-$3.51B
Diluted EPS	1.71	0.05	-0.53	-3.00
Diluted Shares	1.22B	1.21B	1.19B	1.17B

VTRS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.26B	$991.90M	$734.80M	$1.32B
Receivables	$4.14B	$4.04B	$3.52B	$3.35B
Inventory	$3.52B	$3.47B	$3.85B	$4.00B
Current Assets	$10.64B	$12.98B	$9.52B	$9.79B
Total Assets	$50.02B	$47.69B	$41.50B	$37.19B
Current Liabilities	$6.75B	$7.78B	$5.78B	$7.09B
Long-Term Debt	$18.02B	$16.19B	$14.04B	$12.48B
Total Debt	$19.53B	$18.37B	$14.31B	$14.70B
Total Liabilities	$28.95B	$27.22B	$22.87B	$22.48B
Retained Earnings	$5.18B	$4.64B	$3.42B	-$388.30M
Shareholders' Equity	$21.07B	$20.47B	$18.64B	$14.71B
Working Capital	$3.89B	$5.20B	$3.74B	$2.69B
Net Debt	$18.01B	$17.13B	$13.30B	$13.09B

VTRS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$3.00B	$2.90B	$2.30B	$2.32B
Capital Expenditure	-$489.40M	-$574.90M	-$359.10M	-$465.10M
Free Cash Flow	$2.51B	$2.33B	$1.94B	$1.85B
Depreciation & Amortisation	$3.03B	$2.74B	$2.89B	$2.80B
Stock-Based Compensation	$116.40M	$180.70M	$146.10M	$177.70M
Investing Cash Flow	$1.47B	-$864.50M	$1.80B	-$427.70M
Financing Cash Flow	-$3.88B	-$2.30B	-$4.33B	-$1.29B
Dividends Paid	-$581.60M	-$575.60M	-$574.80M	-$561.20M
Share Repurchases	$0.00	-$250.00M	-$250.00M	-$500.50M
Net Change in Cash	$595.20M	-$266.40M	-$226.80M	$594.30M

VTRS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$3.25B	$3.58B	$3.76B	$3.70B	$3.52B
Cost of Revenue	$2.09B	$2.25B	$2.39B	$2.56B	$2.36B
Gross Profit	$1.16B	$1.33B	$1.37B	$1.15B	$1.16B
Research & Development	$222.00M	$218.80M	$250.40M	$274.70M	$248.60M
Selling, General & Admin	$948.10M	$928.70M	$886.60M	$1.03B	$928.80M
Operating Expenses	$1.17B	$1.15B	$1.14B	$1.31B	$1.18B
Operating Income	-$8.90M	$185.40M	$234.50M	-$157.50M	-$20.20M
EBITDA	-$2.32B	$577.80M	$800.20M	$543.40M	$548.90M
Pretax Income	-$3.10B	-$217.10M	-$7.90M	-$343.00M	-$247.30M
Income Tax	-$55.00M	-$212.50M	$120.30M	-$2.90M	-$423.70M
Net Income	-$3.04B	-$4.60M	-$128.20M	-$340.10M	$176.40M
Diluted EPS	-2.55	0.00	-0.11	-0.30	0.15
Diluted Shares	1.19B	1.17B	1.16B	1.15B	1.18B

VTRS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$755.00M	$566.40M	$975.30M	$1.32B	$1.80B
Receivables	$3.39B	$3.60B	$3.59B	$3.35B	$3.74B
Inventory	$4.10B	$4.26B	$4.11B	$4.00B	$3.93B
Current Assets	$9.62B	$9.77B	$9.95B	$9.79B	$10.92B
Total Assets	$38.47B	$38.41B	$37.92B	$37.19B	$36.83B
Current Liabilities	$5.72B	$7.13B	$7.36B	$7.09B	$6.81B
Long-Term Debt	$14.18B	$12.79B	$12.49B	$12.48B	$12.41B
Total Debt	$14.46B	$14.76B	$14.72B	$14.70B	$14.61B
Total Liabilities	$22.82B	$22.84B	$22.70B	$22.48B	$22.18B
Retained Earnings	$227.90M	$80.00M	-$48.20M	-$388.30M	-$211.90M
Shareholders' Equity	$15.65B	$15.57B	$15.22B	$14.71B	$14.66B
Working Capital	$3.90B	$2.64B	$2.59B	$2.69B	$4.11B
Net Debt	$13.42B	$13.90B	$13.46B	$13.09B	$12.54B

VTRS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$535.50M	$219.70M	$744.90M	$815.80M	$388.30M
Capital Expenditure	-$76.40M	-$54.10M	-$99.70M	-$234.90M	-$124.20M
Free Cash Flow	$459.10M	$165.60M	$645.20M	$580.90M	$264.10M
Depreciation & Amortisation	$664.70M	$678.30M	$688.50M	$766.80M	$676.10M
Stock-Based Compensation	$55.20M	$37.10M	$36.00M	$49.40M	$48.20M
Investing Cash Flow	-$65.10M	-$52.50M	-$98.90M	-$211.20M	$277.40M
Financing Cash Flow	-$467.00M	-$362.40M	-$228.10M	-$236.40M	-$203.80M
Dividends Paid	-$143.30M	-$139.80M	-$139.90M	-$138.20M	-$139.60M
Share Repurchases	-$175.40M	-$175.00M	-$65.00M	-$85.10M	$0.00
Net Change in Cash	$3.40M	-$195.20M	$417.90M	$368.20M	$461.90M

Market Snapshot

About

Viatris is a global healthcare company formed through the merger of Mylan and Upjohn, a division of Pfizer. The company focuses on developing, manufacturing, and distributing generic and branded pharmaceutical products across a wide range of therapeutic categories. Viatris serves patients in more than 165 countries with a mission to expand access to quality medicines worldwide.